Table 2 Comparison of clinical effectiveness between dulaglutide and liraglutide users (based on the study sample after propensity score matching)
|  | Dulaglutide (n = 983) | Liraglutide (n = 983) | Dulaglutide versus liraglutide | ||
|---|---|---|---|---|---|
Baseline (SD) | Change from baseline (SE) | Baseline (SD) | Change from baseline (SE) | Mean difference (95% CI) | |
Analysis for the change before and after 12Â monthsa | |||||
 HbA1c (%) | 9.36 (1.66) | − 1.06 (0.05)*** | 9.33 (1.57) | − 0.83 (0.05)*** | − 0.23 (− 0.38 to − 0.08)** |
 Weight (kg) | 77.83 (17.69) | − 1.14 (0.30)*** | 77.53 (16.81) | − 1.64 (0.31)*** | 0.49 (− 0.35 to 1.35) |
 SBP (mmHg) | 140.71 (19.94) | − 2.47 (0.69)*** | 140.24 (20.24) | − 0.56 (0.72) | − 1.90 (− 3.87 to 0.06) |
 ALT (U/L) | 36.10 (30.23) | − 3.08 (0.82)*** | 35.47 (32.66) | − 3.65 (0.91)*** | 0.57 (− 1.84 to 2.98) |
 eGFR (mL/min/1.73 m2) | 82.43 (38.21) | − 2.08 (0.69)** | 82.13 (35.69) | − 2.33 (0.62)*** | 0.24 (− 1.58 to 2.07) |
Analysis for repeated changes at every 3Â months over 1Â yearb | |||||
 HbA1c (%) | 9.36 (1.66) | − 1.09 (0.07)*** | 9.33 (1.57) | − 0.78 (0.07)*** | -0.27 (− 0.43 to − 0.12)*** |
 Weight (kg) | 77.83 (17.69) | − 1.08 (0.35)** | 77.53 (16.81) | − 1.41 (0.35)*** | 0.82 (− 0.76 to 2.41) |
 SBP (mmHg) | 140.71 (19.94) | − 2.36 (0.93)* | 140.24 (20.24) | − 0.31 (0.93) | − 1.55 (− 3.52 to 0.40) |
 ALT (U/L) | 36.10 (30.23) | − 3.72 (1.63)* | 35.47 (32.66) | − 3.85 (1.66)* | 0.65 (− 3.01 to 4.31) |
 eGFR (mL/min/1.73 m2) | 82.43 (38.21) | − 2.49 (1.06)* | 82.13 (35.69) | − 2.09 (1.05)* | − 0.56 (− 3.99 to 2.85) |